Worm.com

Radialpoint, a leading provider of managed Internet security and care services to the world’s largest Internet Service Providers (ISPs), today announced that it has joined the Anti-Virus Product Developers Consortium (AVPD). Led by ICSA Labs, an independent division of Verizon Business, the industry group develops criteria standards and conducts certification testing of anti-virus products and solutions.

Since its inception in 1991, the consortium has attracted an international group of anti-virus software developers that represent many of today’s market leaders. The mission of the AVPD is to use the expertise of its members to continually identify and evaluate security issues, develop certification guidelines, design knowledge and information-based solutions, and promote confidence in the use of anti-virus products worldwide.

“The insight we’re gaining from Radialpoint’s experience with malware issues will assist ICSA Labs in developing criteria that allow for objective product testing,” said George Japak, managing director, ICSA Labs. “Together, ICSA Labs, Radialpoint and the Anti-Virus Product Developers Consortium are driving the development of superior products through testing and certification, and increasing customer confidence in their functionality.”

The Radialpoint Virus Protection Service helps defend against threats such as viruses, Trojans and worms by scanning, detecting and disinfecting the subscriber’s computer. The service automatically updates, keeping users constantly protected. The Radialpoint Virus Protection Service is currently available in North America and Europe through vendors including Verizon, Bell Canada, TELUS and Virgin Media.

“Protecting consumers online isn’t the job of a single organization or company, but the industry as a whole. We are excited to be working with other leaders in the field to strengthen our collective response to the pervasive threat of computer viruses,” said Hamnett Hill, CEO of Radialpoint. “Through our participation in the ICSA Labs Anti-Virus Product Developers Consortium, we reinforce our commitment to helping create a better, safer Internet and continue to develop the best possible protective technologies for our ISP partners and their subscribers.”

ICSA Labs offers vendor-neutral testing and certification for hundreds of the world’s top security products including many of the anti-virus, firewall, IPSec VPN, SSL VPN, network IPS and anti-spyware products commonly deployed today.

About ICSA Labs

ICSA Labs, an independent division of Verizon Business, offers vendor-neutral testing and certification of security products. Many of the world’s top security vendors submit their products for testing and certification at ICSA Labs. Businesses rely on ICSA Labs to authoritatively set and apply objective testing and certification criteria for measuring product compliance and reliability. For more information about ICSA Labs, please visit: http://www.icsalabs.com .

About Radialpoint

Radialpoint is a leading provider of managed Internet security and care services for Internet service providers (ISPs). Its Value Added Services (VAS) are currently available to over 20 million broadband subscribers worldwide. Radialpoint’s Services and Managed VAS Platform enable ISPs to generate new revenue and significantly lower operational costs associated with supporting and bringing new Internet services to market. Its customers include Bell Aliant, Bell Canada, TELUS and Videotron in Canada; AT&T/ BellSouth and Verizon in the US; and, ONO, and Virgin Media in Europe. Radialpoint is headquartered in Montreal, Canada, with offices in Europe.

For more information, visit http://www.radialpoint.com/ .

Contacts:
Radialpoint
Cathy Stojak
Media Relations
cathy.stojak@radialpoint.com
1-514-286-2636 x2806

High Road Communications
Michael Sznajdruk
msznajdruk@highroad.com
613-688-1189

Information provided by: Findarticles.com

Leading Internet Security Vendor Completes Process in Record Time

ORLANDO, Fla. and BRNO, Czech Republic, June 25 /PRNewswire/ — AVG Technologies, a leading provider of Internet security software, today announced it has attained Gold Certified status in the Microsoft Partner Program with a competency in ISV/Software Solutions. To qualify as a Gold Certified partner, the company demonstrated expertise with Microsoft technologies and a proven ability to meet customers’ needs using that technology. Microsoft Gold Certified Partners receive a rich set of benefits, including access, training and support, enabling them to provide optimum service and support to their customers.

AVG Technologies offers a range of Internet security products for home users and small to medium sized businesses (SMB). Home users can choose AVG Anti-Virus, AVG Anti-Virus plus Firewall, or AVG Internet Security, while business users can select networked versions of the Anti-Virus and Internet Security products as well as file- and email-server based Anti-Virus. In addition, AVG Technologies provides free basic protection against viruses, spyware, and web threats delivered through search results pages, to individuals with AVG Free.

"We are extremely pleased to have achieved Gold Certified status in the Microsoft Partner Program," says AVG Technologies CEO J. R. Smith. "It clearly shows our customers and business partners the high degree of expertise our people have in the use and support of Microsoft tools and platforms. Everyone gains from this recognition."

As one of the requirements for attaining Gold Certified Status, AVG Technologies had to declare a Microsoft Competency. Microsoft Competencies are designed to help differentiate a partner’s capabilities with specific Microsoft technologies to customers looking for a particular type of solution. Each competency has a unique set of requirements and benefits, formulated to accurately represent the specific skills and services that partners bring to the technology industry.

The Microsoft ISV/Software Solutions Competency recognizes the skill and focus partners bring to a particular solution set. Microsoft Gold Certified Partners that have obtained this competency have a successful record of developing and marketing packed software based on Microsoft technologies.

AVG Technologies recently announced that the AVG Free basic security product has achieved a key milestone of five million downloads in a single week at CNet download.com (http://www.download.com/). AVG Free was downloaded more than five million times during the last week of May 2008. The total number of downloads through download.com since the launch of AVG Free 8.0 in April 2008 and today is approaching 25 million.

About the Microsoft Partner Program

The Microsoft Partner Program was launched in December 2003 and represents Microsoft’s ongoing commitment to the success of partners worldwide. The program offers a single, integrated partnering framework that recognizes partner expertise, rewards the total impact that partners have in the technology marketplace, and delivers more value to help partners’ businesses be successful.

About AVG Technologies

Founded in 1991 in the Czech Republic, AVG is a leading international developer of Internet threat protection solutions for consumers and SMBs. AVG protects more than 70 million computer users around the world. The company has offices in Europe and North America and employs some of the world’s leading experts in Internet security, specifically in the areas of threat research, analysis and detection. AVG’s award-winning products are distributed globally through resellers and over the Internet as well as via third parties through Software Development Kits (SDKs).

Further information may be found on the company’s website at http://www.avg.com/.

AVG investors include:

Enterprise Investors (http://www.ei.com.pl/english/index.php), based in Poland, Benson Oak (http://www.bensonoak.com/en/praxe.html), based in the Czech Republic and Intel Corp.’s venture arm Intel Capital (http://www.intel.com/capital/) based in the US.

CONTACT: Bryan Ferraro or Julie Parayno of Dovetail Public Relations, +1-408-395-3600, avg at dovetailpr dot com

Web site: http://www.avg.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Fortinet® — the pioneer and leading
provider of unified threat management (UTM) solutions — today announced
that Community Health Resources (CHR) has deployed a Fortinet FortiGate®
multi-threat security appliance to help secure its network from malicious
Internet attacks. CHR initially planned to deploy the FortiGate appliance
for firewall protection, replacing an underperforming competitive solution.
Upon seeing the strength of the Fortinet firewall, the agency decided to
implement additional Fortinet security functions including antivirus,
intrusion prevention (IPS) and Web filtering protection while maintaining a
low total cost of ownership and ease of management.

Community Health Resources is a private, non-profit, community-based system
of behavioral health care dedicated to helping people of all ages lead
happier and healthier lives. As CHR continually expands its service
offerings to better serve the community needs in Connecticut, its network
security needs are also expanding.

CHR’s previous firewall solution was periodically rebooting on its own
which would cause throughput and latency issues. Also adding to network
problems was CHR IT staff’s inability to add new employees to the firewall
profile. With these two problems, CHR turned to KDSA Consulting, LLC, an
information technology consulting firm specializing in outsourced network
administration and financial accounting software solutions, to help find a
network security solution that would increase up-time while lowering total
cost of ownership and enabling the network to scale in-line with the
agency.

“We were looking to simplify network management and wanted a robust and
consolidated security solution so that we didn’t have to have multiple
people managing the network,” said Jason Francia, senior network
administrator for Community Health Resources. “The Fortinet solution is
allowing us enterprise-level security that is easy to use and meets our
growing needs.”

Fortinet’s FortiGate-400A multi-threat security solution is helping to
provide firewall, antivirus, IPS and Web filtering protection at CHR’s
Windsor, Conn. headquarters. CHR’s ability to add advanced network security
functions to its initial firewall requirements is due to Fortinet’s
integrated and scalable multi-threat security solution. Without having to
deploy new point products, CHR easily added security functionalities to its
network and thereby lowered the total cost of ownership.

Soon to be added to the CHR network are several of their residential
programs located throughout northern Connecticut. These homes house
children and adolescents and will be using Fortinet for Web filtering so
that the children are unable to access inappropriate Websites. Currently,
the homes are not connected to the CHR network and, therefore, no
restrictions are placed on Internet usage.

“Non-profit agencies like Community Health Resources are forced to be cost
conscious yet need enterprise-level network security,” said Karl Soderlund,
vice president of Americas sales and business development for Fortinet.
“Fortinet’s consolidated network security approach allows for agencies such
as CHR to easily scale to its growing needs by adding network security
functionality without the burden of working with additional vendors or
adding headcount.”

Fortinet provides ASIC-accelerated security appliances, which are used by
enterprises and service providers to enhance and consolidate their security
needs while reducing total operating costs. Fortinet solutions were built
from the ground up to integrate multiple levels of security protection –
including firewall, antivirus, intrusion prevention, VPN, Web filtering,
spyware prevention and anti-spam — designed to help customers protect
against network and content level threats. Delivered via its flagship
FortiGate family of appliances, Fortinet provides a flexible and extensible
platform of security applications and services that enable customers to
deploy and centrally manage the same broad level of protection at remote
locations as they have for headquarters and data center environments.

About Community Health Resources ( www.chrhealth.org )

Community Health Resources is one of the leading providers of community
mental health care in the state of Connecticut. Each year, CHR helps
thousands of adults, children and families successfully live with mental
illness. CHR’s professional staff, who are committed to recovery, provide
treatment, support, rehabilitation, prevention and educational services to
those in need.

About KDSA Consulting, LLC ( www.kdsaconsulting.com )

KDSA Consulting, LLC located in North Andover, MA provides the full
spectrum of information technology services for small to medium sized
businesses and not-for-profit organizations. Our infrastructure division
designs local and wide area networks, disaster recovery solutions and
provides contracted “managed services” support to end users. Our software
division performs system selection consulting, financial accounting project
management, implementation and training along with customized programming
and database management services.

Information provided by: Findarticles.com

Expert in Virus-Cell Interactions had Proposed Blocking them as a Possible Treatment

WEST HAVEN, Conn. — NanoViricides, Inc. (OTC BB: NNVC.OB), (the "Company") said that noted Yale University School of Medicine research physician, Thomas Lentz, MD, has agreed to join the NanoViricides’ Scientific Advisory Board (SAB).

In accepting the invitation, Dr. Lentz commented by email, "As you know, I was an early proponent of the possibility of treating viral infections by blocking the virus-receptor interaction. While most attempts at putting this into practice have not been successful, I believe the innovative approach employed by NanoViricides has great potential."

Professor Lentz’s research has laid the early foundations for developing anti-viral therapies by blocking virus-cell receptor interactions. His work on the binding of rabies virus to the nicotinic acetylcholine receptor has helped in the creation of a rabies-specific nanoviricide. In addition, his extensive studies on the classification of viruses and of their cellular receptors into broad groups provided the basis for the broad-spectrum nanoviricides that the Company is developing at present as potent therapeutics against a large number of viruses.

Dr. Lentz, whose current title is Senior Research Scientist and Professor Emeritus of Cell Biology was previously also Associate Dean for Admissions and Financial Aid at the School of Medicine (http://www.cellbiology.yale.edu/cellbio/html/faculty/t_lentz.shtml).

"It is needless to say that to have Professor Lentz join our SAB is indeed an honor," commented Dr. Anil Diwan, President of the Company, adding, "We have already benefited substantially from his extensive research in the virus-cell interactions field. His association with the Company should help us tremendously in our mission of destroying viruses in the body and conquering viral diseases."

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company’s novel nanoviricide[TM] class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC (epidemic kerato-conjunctivitis or severe pink eye disease), hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company’s research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management’s Discussion and Analysis" section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

BLUE BELL, Pa. — VGX Pharmaceuticals Inc. (VGX) announced today the publication in PLoS ONE - an international, peer-reviewed, open-access, online publication - of preclinical data for the Company’s preventative DNA vaccine candidate for avian influenza, VGX-3400. The article, titled "Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens", is available at www.plosone.org/doi/pone.0002517.

The highly pathogenic Avian Influenza (HPAI), or "bird flu", virus is an emerging threat that has killed millions of poultry in a growing number of countries. Health experts are concerned that the co-existence of human flu viruses and avian flu viruses (primarily subtype H5N1) will provide an opportunity for genetic material to be exchanged between species-specific viruses, possibly creating a new virulent influenza strain that is easily transmissible and lethal to humans. The pandemic potential of bird flu highlights the need for novel vaccination techniques that can quickly and effectively respond to emerging viral threats.

This study evaluated the use of optimized consensus (SynCon[TM]) influenza antigens to provide broad protection against divergent strains of H5N1 influenza in mouse, ferret, and non-human primate models. Responses in all three species tested demonstrate the ability of SynCon[TM] antigens to induce production of protective antibodies capable of providing cross-protection from divergent strains of the H5N1 subtype. Both ferrets and mice vaccinated with the SynCon[TM] antigens were 100% protected from lethal influenza challenge, with significant reductions in viral shedding and disease progression in vaccinated ferrets. These studies also demonstrated the effective use of the Company’s CELLECTRA[R] constant current electroporation device in combination with the SynCon[TM] antigens to provide protection in larger animal models.

"Publication of this study emphasizes the potential of VGX technology to improve human health and safety," stated Dr. J. Joseph Kim, President and Chief Executive Officer. "We are optimistic that our novel vaccine program will significantly expand the prevention options for influenza."

VGX Pharmaceuticals is awaiting approval from the Food and Drug Administration to study the avian flu vaccine (VGX-3400) in humans.

About VGX Pharmaceuticals

More information about VGX can be found at www.vgxp.com.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

SAN DIEGO — Aethlon Medical, Inc. (OTCBB:AEMD) disclosed this evening that its CEO, James A. Joyce, is currently featured in an on-line interview with CEOcast, Inc. During the interview, Mr. Joyce discusses the "first-in-man" clinical study of the Aethlon Hemopurifier[R] as a treatment for HIV/AIDS. The Hemopurifier[R], which provides real-time therapeutic filtration of infectious viruses and immunosuppressive proteins, holds promise to extend the lives of AIDS patients by removing HIV strains that cause drug failure and reducing the presence of viral proteins that kill-off immune cells. The interview is now available to be accessed through a free registration at http://www.ceocast.com.

About CEOcast

CEOcast produces original and syndicated streaming broadcast interviews of chief executive officers at public and private news-making companies and distributes its programming to millions of online investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device designed to treat infectious disease. The Hemopurifier[R] provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier[R] is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier[R] is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier[R] in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier[R] as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier[R] in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The company has submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier([R]) as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier([R]) technology is available online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Medicago Inc. (TSX VENTURE: MDG) today announced additional positive results for the Company’s H5N1 Avian Influenza VLP vaccine from a preclinical immunogenicity study performed in ferrets, the most predictive animal model for evaluating the effectiveness of influenza vaccines in humans. The Company’s H5N1 VLP vaccine induced high levels of antibodies that neutralized strains of H5N1 circulating virus beyond the strain used to develop the original vaccine. Cross-reactivity was demonstrated against three of the deadliest strains of H5N1: the Turkey strain (clade 2.2), the Anhui strain (clade 2.3) and the Vietnam strain (clade 1).

“These data further highlight the competitive advantages of our proprietary avian flu vaccine. Not only have we been able to demonstrate the efficacy of our vaccine at very low doses, we have now demonstrated that our vaccine offers broad protection against a variety of strains of this deadly virus,” said Andy Sheldon, President and CEO of Medicago. “These unique properties, combined with the speed of our vaccine production platform, should prove highly attractive to governments and institutions seeking to develop vaccine stockpiles and pandemic planning in the most efficient and effective manner possible.”

The objective of Medicago’s study was to determine the optimal dosage for its H5N1 VLP vaccine in ferrets. At the start of the study, ferrets were vaccinated with a range of doses of the Company’s VLP vaccine made from an Indonesian strain of H5N1 Avian Influenza. A booster immunization was administered after three weeks. The results demonstrated that ferrets vaccinated with the 5 micrograms dose met all CHMP (European Union Committee for Medicinal Products for Human Use) criteria for other H5N1 strains after the second dose with 100% of the ferrets having an hemagglutination inhibition (HAI) titer greater than 1:40 for the Turkey strain, and 80%, for the Anhui and Vietnam strains. These criteria set by the CHMP for the approval of seasonal flu vaccines in the European Union are widely used to assess immune responses of new pandemic influenza vaccines in humans. In the case of ferrets, these criteria are useful to predict effective doses that should be tested in humans.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com .

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release.

Contacts:
Medicago, Inc.
Andy Sheldon
President and CEO
418-658-9393

The Equicom Group Inc.
Arianna Vanin
Investor relations
514-844-4680
avanin@equicomgroup.com

Information provided by: Findarticles.com